• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

脉络膜新生血管动物模型:系统评价。

Animal Models of Choroidal Neovascularization: A Systematic Review.

机构信息

Department of Biomedicine, Aarhus University, Aarhus, Denmark.

Department of Ophthalmology, Aarhus University Hospital, Aarhus, Denmark.

出版信息

Invest Ophthalmol Vis Sci. 2022 Aug 2;63(9):11. doi: 10.1167/iovs.63.9.11.

DOI:10.1167/iovs.63.9.11
PMID:35943733
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9379329/
Abstract

PURPOSE

Animal models of choroidal neovascularization (CNV) are extensively used to characterize the pathophysiology of chorioretinal diseases with CNV formation and to evaluate novel treatment strategies. This systematic review aims to give a detailed overview of contemporary animal models of CNV.

METHODS

A systematic search was performed in PubMed and EMBASE from November 20, 2015, to November 20, 2020, for mammalian animal models of CNV. Following inclusion by two investigators, data from the articles were extracted according to a predefined protocol.

RESULTS

A total of 380 full articles, representing 409 independent animal models, were included. Mice were by far the most utilized animal (76%) followed by rats and non-human primates. The median age of rodents was 8 weeks but with a wide range. Male animals were used in 44% of the studies, but 32% did not report the sex. CNV was laser induced in 89% of the studies, but only 44% of these reported sufficiently on standard laser parameters. Surprisingly, 28% of the studies did not report a sample size for quantitative CNV evaluation. Less than half of the studies performed quantitative in vivo evaluation, and 73% evaluated CNV quantitatively ex vivo. Both in vivo and ex vivo evaluations were conducted primarily at day 7 and/or day 14.

CONCLUSIONS

The laser-induced mouse model is the predominant model for experimental CNV. The widespread use of young, healthy male animals may complicate clinical translation, and inadequate reporting challenges reproducibility. Definition and implementation of standardized methodologic and reporting guidelines are attractive.

摘要

目的

脉络膜新生血管(CNV)动物模型被广泛用于研究伴有 CNV 形成的眼后段疾病的病理生理学,并评估新的治疗策略。本系统综述旨在详细概述当前的 CNV 动物模型。

方法

我们于 2015 年 11 月 20 日至 2020 年 11 月 20 日在 PubMed 和 EMBASE 中进行了系统性检索,以获取 CNV 哺乳动物动物模型的相关研究。两名研究者进行纳入后,根据预先设定的方案提取文章中的数据。

结果

共纳入 380 篇全文,代表 409 个独立的动物模型。小鼠是迄今为止使用最广泛的动物(76%),其次是大鼠和非人类灵长类动物。啮齿动物的中位年龄为 8 周,但范围较宽。44%的研究使用雄性动物,但 32%的研究未报告性别。89%的研究采用激光诱导 CNV,但仅有 44%的研究充分报告了标准激光参数。令人惊讶的是,28%的研究未报告定量 CNV 评估的样本量。不到一半的研究进行了定量体内评估,73%的研究进行了定量离体评估。体内和离体评估主要在第 7 天和/或第 14 天进行。

结论

激光诱导的小鼠模型是实验性 CNV 的主要模型。广泛使用年轻、健康的雄性动物可能会使临床转化复杂化,并且不充分的报告也会对可重复性造成挑战。制定和实施标准化的方法学和报告指南具有吸引力。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/448e/9379329/01a507d3fe0d/iovs-63-9-11-f003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/448e/9379329/2f2017939bc8/iovs-63-9-11-f001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/448e/9379329/86133eeb2c5f/iovs-63-9-11-f002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/448e/9379329/01a507d3fe0d/iovs-63-9-11-f003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/448e/9379329/2f2017939bc8/iovs-63-9-11-f001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/448e/9379329/86133eeb2c5f/iovs-63-9-11-f002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/448e/9379329/01a507d3fe0d/iovs-63-9-11-f003.jpg

相似文献

1
Animal Models of Choroidal Neovascularization: A Systematic Review.脉络膜新生血管动物模型:系统评价。
Invest Ophthalmol Vis Sci. 2022 Aug 2;63(9):11. doi: 10.1167/iovs.63.9.11.
2
Porcine models of choroidal neovascularization: A systematic review.猪脉络膜新生血管模型:系统评价。
Exp Eye Res. 2023 Sep;234:109590. doi: 10.1016/j.exer.2023.109590. Epub 2023 Jul 19.
3
Imaging Laser-Induced Choroidal Neovascularization in the Rodent Retina Using Optical Coherence Tomography Angiography.使用光学相干断层扫描血管造影术对啮齿动物视网膜中的激光诱导脉络膜新生血管进行成像。
Invest Ophthalmol Vis Sci. 2016 Jul 1;57(9):OCT331-40. doi: 10.1167/iovs.15-18946.
4
In-vivo and ex-vivo characterization of laser-induced choroidal neovascularization variability in mice.在体和离体评价小鼠激光诱导脉络膜新生血管变异性。
Graefes Arch Clin Exp Ophthalmol. 2012 Nov;250(11):1579-86. doi: 10.1007/s00417-012-1990-z. Epub 2012 Mar 16.
5
Effect of chromogranin A-derived vasostatin-1 on laser-induced choroidal neovascularization in the mouse.嗜铬粒蛋白A衍生的血管抑素-1对小鼠激光诱导脉络膜新生血管形成的影响。
Acta Ophthalmol. 2015 May;93(3):e218-22. doi: 10.1111/aos.12557. Epub 2014 Oct 1.
6
Visible-Light Optical Coherence Tomography Angiography for Monitoring Laser-Induced Choroidal Neovascularization in Mice.用于监测小鼠激光诱导脉络膜新生血管的可见光光学相干断层扫描血管造影术
Invest Ophthalmol Vis Sci. 2016 Jul 1;57(9):OCT86-95. doi: 10.1167/iovs.15-18891.
7
Reliability of the mouse model of choroidal neovascularization induced by laser photocoagulation.激光光凝诱导脉络膜新生血管小鼠模型的可靠性
Invest Ophthalmol Vis Sci. 2014 Sep 9;55(10):6525-34. doi: 10.1167/iovs.14-15067.
8
Effect of brimonidine on retinal and choroidal neovascularization in a mouse model of retinopathy of prematurity and laser-treated rats.溴莫尼定对早产儿视网膜病变模型小鼠和激光处理大鼠的视网膜和脉络膜新生血管的影响。
Invest Ophthalmol Vis Sci. 2011 Jul 20;52(8):5424-31. doi: 10.1167/iovs.10-6262.
9
A new hand-held holder optimizes the parameters of the laser-induced choroidal neovascularization model in mice.一种新型手持式固定器优化了小鼠激光诱导脉络膜新生血管模型的参数。
Exp Eye Res. 2021 Feb;203:108392. doi: 10.1016/j.exer.2020.108392. Epub 2020 Dec 15.
10
Optimization of laser-induced choroidal neovascularization in African green monkeys.优化非洲绿猴的激光诱导脉络膜新生血管。
Exp Eye Res. 2011 Jun;92(6):464-72. doi: 10.1016/j.exer.2011.03.006. Epub 2011 Mar 22.

引用本文的文献

1
Factor-H-related protein 1 (FHR1), a promotor of para-inflammation in age-related macular degeneration.补体因子H相关蛋白1(FHR1),年龄相关性黄斑变性中旁炎症的促进因子。
J Neuroinflammation. 2025 Jul 3;22(1):173. doi: 10.1186/s12974-025-03499-z.
2
AZGP1 Attenuates Subretinal Fibrosis and Inhibits Epithelial-Mesenchymal Transition by Blocking the PI3K/AKT Signaling Pathway.AZGP1通过阻断PI3K/AKT信号通路减轻视网膜下纤维化并抑制上皮-间质转化。
Invest Ophthalmol Vis Sci. 2025 Apr 1;66(4):83. doi: 10.1167/iovs.66.4.83.
3
Supramolecular Engineering of Nanoceria for Management and Amelioration of Age-Related Macular Degeneration via the Two-Level Blocking of Oxidative Stress and Inflammation.

本文引用的文献

1
Translational science: a survey of US biomedical researchers' perspectives and practices.转化科学:对美国生物医学研究人员观点和实践的调查。
Lab Anim (NY). 2022 Jan;51(1):22-35. doi: 10.1038/s41684-021-00890-0. Epub 2021 Dec 23.
2
Pipeline therapies for neovascular age related macular degeneration.用于新生血管性年龄相关性黄斑变性的流水线疗法。
Int J Retina Vitreous. 2021 Oct 1;7(1):55. doi: 10.1186/s40942-021-00325-5.
3
Subretinal Saline Protects the Neuroretina From Thermic Damage During Laser Induction of Experimental Choroidal Neovascularization in Pigs.
通过氧化应激和炎症的两级阻断对纳米氧化铈进行超分子工程设计以管理和改善年龄相关性黄斑变性
Adv Sci (Weinh). 2025 Mar;12(9):e2408436. doi: 10.1002/advs.202408436. Epub 2025 Jan 10.
4
Functional Roles of Pigment Epithelium-Derived Factor in Retinal Degenerative and Vascular Disorders: A Scoping Review.色素上皮衍生因子在视网膜退行性和血管性疾病中的功能作用:一项范围综述
Invest Ophthalmol Vis Sci. 2024 Dec 2;65(14):41. doi: 10.1167/iovs.65.14.41.
5
Intravitreal Metformin Protects Against Choroidal Neovascularization and Light-Induced Retinal Degeneration.玻璃体腔内二甲双胍可预防脉络膜新生血管和光诱导的视网膜变性。
Int J Mol Sci. 2024 Oct 22;25(21):11357. doi: 10.3390/ijms252111357.
6
Subretinal AAV delivery of RNAi-therapeutics targeting reduces choroidal neovascularization in a large animal model.在大型动物模型中,通过视网膜下注射腺相关病毒(AAV)递送靶向RNA干扰疗法可减少脉络膜新生血管形成。
Mol Ther Methods Clin Dev. 2024 Mar 22;32(2):101242. doi: 10.1016/j.omtm.2024.101242. eCollection 2024 Jun 13.
7
Exploring the Impact of Saccharin on Neovascular Age-Related Macular Degeneration: A Comprehensive Study in Patients and Mice.探讨糖精对新生血管性年龄相关性黄斑变性的影响:一项在患者和小鼠中的综合研究。
Invest Ophthalmol Vis Sci. 2024 Apr 1;65(4):5. doi: 10.1167/iovs.65.4.5.
8
Systemic Dendrimer-Peptide Therapies for Wet Age-Related Macular Degeneration.用于湿性年龄相关性黄斑变性的全身性树枝状聚合物-肽疗法。
Pharmaceutics. 2023 Oct 5;15(10):2428. doi: 10.3390/pharmaceutics15102428.
9
Assessment of Inner Blood-Retinal Barrier: Animal Models and Methods.内眼血视网膜屏障评估:动物模型与方法。
Cells. 2023 Oct 12;12(20):2443. doi: 10.3390/cells12202443.
10
Neovascular Progression and Retinal Dysfunction in the Laser-Induced Choroidal Neovascularization Mouse Model.激光诱导脉络膜新生血管小鼠模型中的新生血管进展与视网膜功能障碍
Biomedicines. 2023 Sep 2;11(9):2445. doi: 10.3390/biomedicines11092445.
视网膜下盐水在猪实验性脉络膜新生血管形成的激光诱导过程中保护神经视网膜免受热损伤。
Transl Vis Sci Technol. 2021 Jun 1;10(7):29. doi: 10.1167/tvst.10.7.29.
4
The PRISMA 2020 statement: an updated guideline for reporting systematic reviews.PRISMA 2020 声明:系统评价报告的更新指南。
BMJ. 2021 Mar 29;372:n71. doi: 10.1136/bmj.n71.
5
Associations between the Complement System and Choroidal Neovascularization in Wet Age-Related Macular Degeneration.补体系统与湿性年龄相关性黄斑变性脉络膜新生血管形成之间的关联。
Int J Mol Sci. 2020 Dec 21;21(24):9752. doi: 10.3390/ijms21249752.
6
Systemic Inflammation by Collagen-Induced Arthritis Affects the Progression of Age-Related Macular Degeneration Differently in Two Mouse Models of the Disease.胶原诱导性关节炎引起的系统性炎症在两种疾病小鼠模型中对年龄相关性黄斑变性的进展影响不同。
Invest Ophthalmol Vis Sci. 2020 Dec 1;61(14):11. doi: 10.1167/iovs.61.14.11.
7
Reproducibility of animal research in light of biological variation.鉴于生物学变异性,动物研究的可重复性。
Nat Rev Neurosci. 2020 Jul;21(7):384-393. doi: 10.1038/s41583-020-0313-3. Epub 2020 Jun 2.
8
Preclinical challenges for developing long acting intravitreal medicines.开发长效眼内药物的临床前挑战。
Eur J Pharm Biopharm. 2020 Aug;153:130-149. doi: 10.1016/j.ejpb.2020.05.005. Epub 2020 May 21.
9
Nonresponders to Ranibizumab Anti-VEGF Treatment Are Actually Short-term Responders: A Prospective Spectral-Domain OCT Study.接受雷珠单抗抗血管内皮生长因子治疗无应答者实际上是短期应答者:一项前瞻性的频域光学相干断层扫描研究。
Ophthalmol Retina. 2020 Dec;4(12):1138-1145. doi: 10.1016/j.oret.2019.11.004. Epub 2019 Nov 11.
10
Age-related macular degeneration.年龄相关性黄斑变性。
Lancet. 2018 Sep 29;392(10153):1147-1159. doi: 10.1016/S0140-6736(18)31550-2.